Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma

BACKGROUND: The first line therapy for patients with diffuse large B cell (DLBCL) is R-CHOP. About half of DLBCL patients are either refractory to, or will relapse, after the treatment. Therefore, identifying novel drug targets and effective therapeutic agents is urgently needed for improving DLBCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Liling, Sun, Yuening, Wang, Jinxiang, He, Qingyan, Chen, Xinmei, Lan, Xiaoying, Chen, Jinghong, Dou, Q. Ping, Shi, Xianping, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836452/
https://www.ncbi.nlm.nih.gov/pubmed/31694672
http://dx.doi.org/10.1186/s13046-019-1446-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836452/
https://www.ncbi.nlm.nih.gov/pubmed/31694672
http://dx.doi.org/10.1186/s13046-019-1446-y

Ejemplares similares